KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) EBIT (2017 - 2025)

Guardant Health's EBIT history spans 9 years, with the latest figure at -$120.8 million for Q4 2025.

  • For Q4 2025, EBIT rose 4.1% year-over-year to -$120.8 million; the TTM value through Dec 2025 reached -$437.2 million, up 1.43%, while the annual FY2025 figure was -$437.2 million, 1.43% up from the prior year.
  • EBIT for Q4 2025 was -$120.8 million at Guardant Health, down from -$99.0 million in the prior quarter.
  • Across five years, EBIT topped out at -$97.6 million in Q2 2021 and bottomed at -$197.5 million in Q4 2023.
  • The 5-year median for EBIT is -$115.4 million (2023), against an average of -$120.0 million.
  • The largest annual shift saw EBIT plummeted 208.96% in 2021 before it soared 36.22% in 2024.
  • A 5-year view of EBIT shows it stood at -$98.2 million in 2021, then crashed by 48.79% to -$146.1 million in 2022, then tumbled by 35.17% to -$197.5 million in 2023, then skyrocketed by 36.22% to -$126.0 million in 2024, then grew by 4.1% to -$120.8 million in 2025.
  • Per Business Quant, the three most recent readings for GH's EBIT are -$120.8 million (Q4 2025), -$99.0 million (Q3 2025), and -$106.4 million (Q2 2025).